Infectious pulmonary complications in patients treated with anti-TNF-[alpha] monoclonal antibodies and soluble TNF receptor

Tumor necrosis factor (TNF)-α inhibitors (infliximab, adalimumab, and etanercept) used in immune-mediated inflammatory diseases such as rheumatoid arthritis, Crohn's disease, or psoriatic arthritis have the potential to increase the risk of infectious complications. Pulmonary infections are one...

Full description

Saved in:
Bibliographic Details
Published inCurrent infectious disease reports Vol. 11; no. 3; p. 229
Main Authors Carbone, Javier, Perez-rojas, Javier, Sarmiento, Elizabeth
Format Journal Article
LanguageEnglish
Published Dordrecht Springer Nature B.V 01.05.2009
Subjects
Antibiotics
Antimicrobial agents
Infectious diseases
Medical treatment
Respiratory diseases
Rheumatoid arthritis
Online AccessGet full text

Cover

More Information
Summary:Tumor necrosis factor (TNF)-α inhibitors (infliximab, adalimumab, and etanercept) used in immune-mediated inflammatory diseases such as rheumatoid arthritis, Crohn's disease, or psoriatic arthritis have the potential to increase the risk of infectious complications. Pulmonary infections are one of the most frequent complications associated with the use of TNF inhibitors. This article provides an overview of the distinct types of infectious pulmonary complications seen in patients using these anticytokine drugs. [PUBLICATION ABSTRACT]
ISSN:1523-3847
1534-3146
DOI:10.1007/s11908-009-0034-2